Meng Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Meng Guo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Changlong Li
Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Department of Medical Genetics and Developmental Biology, School of Basic Medical Science, Capital Medical University, Beijing 100069, China
1 shared publication - Jia-Nan Gong
Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
1 shared publication - Jianyi Lv
School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
1 shared publication - Jing Lu
School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
1 shared publication - Jinghui Wang
Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
1 shared publication - Qiuyu Zhang
School of Basic Medical Sciences Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research Beijing P.R. China
1 shared publication
Latest Publications
- 7 September 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (10) , e23170
ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1‐DT and enhancing profilin 2 activation
Small cell lung cancer (SCLC) is one of the most malignant tumors that has an extremely poor prognosis. RNA‐binding protein (RBP) and long noncoding RNA (lncRNA) have been shown to be key regulators during tumorigenesis as well as lung tumor progression. However, the role of RBP ELAVL4 and lncRNA LYPLAL1‐DT in SCLC remains unclear. In this study, we verified that lncRNA LYPLAL1‐DT acts as an SCLC oncogenic lncRNA and was confirmed in vitro and in vivo. Mechanistically , LYPLAL1‐DT negatively regulates the expression of miR‐204‐5p, leading to the upregulation of PFN2, thus, promoting SCLC cell proliferation, migration, and invasion. ELAVL4 has been shown to enhance the stability of LYPLAL1‐DT and PFN2 mRNA. Our study reveals a regulatory pathway, where ELAVL4 stabilizes PFN2 and LYPLAL1‐DT with the latter further increasing PFN2 expression by blocking the action of miR‐204‐5p. Upregulated PFN2 ultimately promotes tumorigenesis and invasion in SCLC. These findings provide novel prognostic indicators as well as promising new therapeutic targets for SCLC.
- 7 September 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (10) , e23170
ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1‐DT and enhancing profilin 2 activation
Small cell lung cancer (SCLC) is one of the most malignant tumors that has an extremely poor prognosis. RNA‐binding protein (RBP) and long noncoding RNA (lncRNA) have been shown to be key regulators during tumorigenesis as well as lung tumor progression. However, the role of RBP ELAVL4 and lncRNA LYPLAL1‐DT in SCLC remains unclear. In this study, we verified that lncRNA LYPLAL1‐DT acts as an SCLC oncogenic lncRNA and was confirmed in vitro and in vivo. Mechanistically , LYPLAL1‐DT negatively regulates the expression of miR‐204‐5p, leading to the upregulation of PFN2, thus, promoting SCLC cell proliferation, migration, and invasion. ELAVL4 has been shown to enhance the stability of LYPLAL1‐DT and PFN2 mRNA. Our study reveals a regulatory pathway, where ELAVL4 stabilizes PFN2 and LYPLAL1‐DT with the latter further increasing PFN2 expression by blocking the action of miR‐204‐5p. Upregulated PFN2 ultimately promotes tumorigenesis and invasion in SCLC. These findings provide novel prognostic indicators as well as promising new therapeutic targets for SCLC.